Intensive Glucose Control in Patients with Type 2 Diabetes - 15-Year Follow-up.

Area of Science:

• Cardiology
• Endocrinology
• Diabetes Research

Background:

• Previous findings indicated a 17% reduction in major cardiovascular events with intensive glucose lowering over 10 years in type 2 diabetes veterans.
• This study reports the full 15-year follow-up data for the original cohort.

Purpose of the Study:

• To evaluate the long-term cardiovascular outcomes and mortality following intensive versus standard glucose control in military veterans with type 2 diabetes.
• To determine if an initial benefit from intensive glucose control persists after glycated hemoglobin levels converge.

Main Methods:

• 1791 participants with type 2 diabetes were followed observationally for 15 years post-trial.
• Cardiovascular events, hospitalizations, and deaths were tracked using central databases.
• A composite outcome of major cardiovascular events and all-cause mortality were the primary and secondary outcomes, respectively.

Main Results:

• Over 15 years, no significant difference in major cardiovascular events or all-cause mortality was observed between intensive and standard glucose control groups.
• A reduced risk of cardiovascular events was noted during the period when glycated hemoglobin levels were separated (HR, 0.83; 95% CI, 0.70 to 0.99).
• This benefit disappeared after glycated hemoglobin levels became similar between groups (HR, 1.26; 95% CI, 0.90 to 1.75).

Conclusions:

• Intensive glucose control in type 2 diabetes provides cardiovascular benefits only during the period of separated glycated hemoglobin levels.
• No lasting legacy effect or mortality benefit was observed with intensive glucose control after treatment equalization.
• The findings suggest that sustained glycemic control differences are crucial for long-term cardiovascular risk reduction.